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Abstract
Background: The COMT gene is located on chromosome 22q11, a region strongly implicated in
the aetiology of several psychiatric disorders, in particular schizophrenia. Previous research has
suggested that activity and expression of COMT is altered in schizophrenia, and is mediated by one
or more polymorphisms within the gene, including the functional Val158Met polymorphism.
Method: In this study we examined the expression levels of COMT mRNA using quantitative RT-
PCR in 60 post mortem cerebellum samples derived from individuals with schizophrenia, bipolar
disorder, depression, and no history of psychopathology. Furthermore, we have examined the
methylation status of two CpG sites in the promoter region of the gene.
Results:  We found no evidence of altered COMT  expression or methylation in any of the
psychiatric diagnoses examined. We did, however, find evidence to suggest that genotype is related
to COMT gene expression, replicating the findings of two previous studies. Specifically, val158met
(rs165688; Val allele) rs737865 (G allele) and rs165599 (G allele) all showed reduced expression
(P < 0.05). Finally, we observe a strong sexual dimorphism in COMT expression, with females
exhibiting significantly greater levels of COMT mRNA.
Conclusion:  The expression of COMT  does not appear to be altered in the cerebellum of
individuals suffering from schizophrenia, bipolar disorder or depression, but does appear to be
influenced by single nucleotide polymorphisms within the gene.
Background
There has been considerable progress in the search for
genes involved in the aetiology of psychiatric disorders
such as schizophrenia. Whilst associations have been
made between polymorphic variants in various genes (e.g.
Neuregulin, Dysbindin, COMT), it is generally not clear
whether the associated polymorphisms are the precise
functional variants mediating susceptibility [1]. In this
study we have examined expression of the Catechol-O-
Methyltransferase (COMT) gene, primarily associated
with schizophrenia, but also linked to other forms of psy-
chopathology and variation in normal prefrontal cogni-
tive functioning (see [1-4]). COMT is a widely expressed
enzyme that metabolises released dopamine in the syn-
apse. In the prefrontal cortex it is the main component in
the dopamine metabolic pathway, since the dopamine
transporter is not abundant in this brain region [5-7].
There are two known promoters in COMT that encode
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two different mRNAs, a longer membrane-bound COMT
(MB-COMT) and a shorter soluble COMT (S-COMT) [8].
Although  COMT, which maps to the velo-cardio-facial
syndrome region located at 22q11, has a well character-
ised functional mutation that alters enzyme activity
(val158met) and is responsible for the majority of varia-
tion in serum COMT activity levels, it is unclear if this
mutation is solely responsible for the association of this
gene and schizophrenia. The met158 allele has been shown
to produce an enzyme with reduced thermostability
[9,10], exhibiting about 60% of the activity of the val158
allele in the brain at normal body temperature [11]. The
alleles are co-dominant, with heterozygotes exhibiting
intermediate activity [12].
Li et al. [13] first found association between schizophre-
nia and the val158 allele, and although there have been
some replications [1,14-16] association results with schiz-
ophrenia have been inconsistent, and largely negative for
depression and bipolar disorder. A recent meta-analysis of
the common val158met polymorphism and schizophrenia
failed to find overall evidence for a significant association
[17,18]. Recent focus has thus shifted to haplotype analy-
sis of the COMT gene in schizophrenia. Li et al. [19] exam-
ined an extended set of markers in the gene and found
strong haplotypic association, which is supported by sub-
sequent haplotype studies by others [20-22]. Population
analysis of the previously typed variants showed widely
differing allele and haplotype frequencies between popu-
lations. It has been postulated that variation in linkage
disequilibrium may account for the inconsistencies seen
in previous association studies focussing on the val158met
SNP [23]. It also indicates that either the val158met poly-
morphism may be a surrogate for a further functional var-
iant involved in the aetiology of schizophrenia, or there
are two sites of functional variation in the gene which are
relevant to psychosis [19]. Shifman et al. (2002), while
finding modest evidence of an association with the
val158met SNP, identified significant association between
schizophrenia and a COMT haplotype consisting of three
SNPs, including val158met, in a large case-control popula-
tion consisting of Ashkenazi Jews [21]. Functional studies
on COMT performed by Bray et al. found that this haplo-
type is associated with a decrease in COMT mRNA expres-
sion [24], an observation that has been replicated by some
groups [25], but not by others (e.g. [11,26]). Handoko et
al. (2005) also found haplotypic association with schizo-
phrenia, with evidence for separate and interacting effects
of SNPs in COMT on susceptibility to the disease [20]. The
success of haplotype analysis of the gene along with
expression work performed by Bray et al. suggests that
COMT regulatory regions may be important in schizo-
phrenia, warranting further expression studies of the gene.
It has been recently suggested that epigenetic factors may
a key role in the development of schizophrenia [27], and
these processes may explain the inconsistent association-
study results often observed for variants in the COMT
gene. Of particular interest is the phenomenon of cytosine
methylation at CpG sites, a molecular process that is
intrinsically linked to the regulation of gene expression.
Methylation at CpG sites, principally located in CpG-
islands in the promoter regulatory regions of many genes,
disrupts the binding of transcription factors and attracts
methyl-binding proteins that are associated with gene
silencing and chromatin compaction. Murphy et al. have
recently examined the methylation status of six CpG sites
in the promoter region of COMT [28]. Using bisulfite-
genomic sequencing they found that four of the sites were
totally methylated in all individuals assessed, but that two
adjacent CpG sites (incorporating cytosines 23 and 27 in
their analysis) showed evidence for only partial methyla-
tion and some degree of between-individual variation.
In this study we have investigated the role of COMT
expression in the development of schizophrenia and two
aetiologically-related psychiatric disorders: bipolar affec-
tive disorder and depression. We have investigated the rel-
ative expression level of COMT  in cerebellum tissue
obtained from post mortem psychiatric patients. Further-
more, we have correlated gene expression levels with gen-
otype for each of the major candidate susceptibility
polymorphisms. Finally, we have accurately quantified
the degree of methylation at the two COMT  promoter
CpG sites to see if epigenetic factors affect gene expression
levels and susceptibility to psychopathology.
Methods
Samples
We obtained 60 post mortem cerebellum brain samples
from The Stanley Medical Research Institute's brain collec-
tion [29]. 15 samples had a diagnosis of schizophrenia, 15
bipolar, 15 depression and 15 controls had no history of
mental illness.
Sample preparation
Both DNA and mRNA were extracted simultaneously
using Trizol following the manufacturer's standard proto-
col (Invitrogen, UK). To ensure no DNA contamination,
clean-up of the RNA was performed using QIAGEN spin
columns with an additional DNAase step (QIAGEN,
Crawley, UK). The quality and purity of total RNA was
assayed in a 2% agarose gel and the recovery was calcu-
lated after measuring absorbance with a spectrophotome-
ter at 260 nm. Reverse Transcription was performed using
TaqMan reverse transcription reagents with random hex-
amers (Applied Biosystems, Foster City, USA). All cDNA
samples were tested for genomic DNA contamination byBMC Medical Genetics 2006, 7:10 http://www.biomedcentral.com/1471-2350/7/10
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PCR amplification of a non-transcribed sequence. Sam-
ples were stored at -70°C prior to further use.
Quantitative PCR
Quantitative RT-PCR was performed in triplicate for each
sample on an ABI Prism 7900HT with TaqMan universal
PCR master mix (Applied Biosystems, Foster City, USA)
using a standard protocol. An Assay-By-Demand probe/
primer set specific to COMT (Hs00241349 _m1), and a β-
Actin housekeeping control gene probe were obtained
from Applied Biosystems (Applied Biosystems, Foster
City, USA). The expression data produced were analysed
and converted into threshold cycle values (Ct-values)
using SDS 2.0 (Applied Biosystems, Foster City, USA). The
comparative CT method (∆∆CT) was used to measure the
relative gene expression. In this method mathematic for-
mulas are used to calculate relative expression levels in
comparison to a 'calibrator' (e.g. a different diagnosis
group). An arbitrary fluorescence threshold is chosen,
based on the variability of the background, and threshold
cycle (CT) values are calculated by determining the cycle
number at which the fluorescence exceeds this threshold.
CT values decrease with increasing input target quantity,
thus, providing a quantitative measure. The amount of
target, normalised to an endogenous housekeeping gene
and relative to a calibrator is then given by the formula 2-
∆∆CT.
CpG methylation analysis
Cerebellum DNA was treated with sodium bisulfite using
a modified version of the protocol outlined by Olek et al.
[30]. Briefly, ~800 ng samples of genomic DNA (in a vol-
ume of 21 µl) were denatured at 95°C for 10 minutes, fol-
lowed by incubation with 4 µl 2 M NaOH solution at
50°C for 15 minutes. DNA was mixed with 50 µl of 2%
low-melting agarose, and 8 µl beads were formed in pre-
chilled mineral oil. Bisulfite conversion was performed
with a 5 M sodium bisulfite solution at 50°C for 4 hours,
under exclusion of light. The beads were washed twice for
15 minutes in TE buffer (pH = 8.0). Desulfonation was
done in 0.2 M NaOH, twice for 15 minutes each, followed
by two additional washing steps, again, with TE buffer.
Single beads were washed with water and used for subse-
quent PCR reactions. Two primers, specific to bisulfite-
treated DNA, were designed on the reverse-complement
strand to flank the two COMT CpG sites (F: 5'-GAG TAG
GTT GTG GAT GGG TTG TA-3' and R: 5'-biotin-ACA TTT
CTA AAC CTT ACC CCT CTA-3'). Purification with
streptavidin beads and Pyrosequencing™ (Biotage, Upp-
sala, Sweden) reactions were performed according to the
manufacturer's standard protocol using the sequencing
primer 5'-GTA ATA TAG TTG TTA ATA GTA GA-3'.
Genotyping
Three common COMT  SNPs (val158met/rs165688,
rs737865, and rs165599) were genotyped using the Amer-
sham SNuPe primer extension assay (GE Healthcare, UK),
and products separated on a MegaBACE capillary system
(GE Healthcare, UK). Primers and assay conditions are
available on request from the authors.
Statistical analysis
Spearman's rank correlations were calculated for the rela-
tionship between COMT  expression and all available
demographic data to determine if any other factors were
contributing to the variation seen in expression. Signifi-
cant correlations were found with the variables: gender
(Rho = -0.366 P = 0.005) and age at death (Rho = -0.340
P = 0.01). To ensure the variation in gender, age and gen-
otype was not confounding the expression differences
seen for the different SNP genotypes, ANCOVA was per-
formed with age, gender and genotype as covariates where
appropriate. All statistical analyses between groups were
performed using SPSS (version 10.0).
Results
Table 1 describes the expression data observed for COMT.
Table 2 describes the association findings. No association
was found between disease status and COMT expression
(F = 0.412, 3 df, p = 0.745). However, genotype at all three
COMT SNPs was found to be associated with gene expres-
sion (p < 0.05), with the G allele of each polymorphism
being correlated with decreased expression. Haplotype
analysis gave further evidence for an association between
COMT genotype and expression with the G-G-G haplo-
type being significantly correlated with reduced expres-
Table 1: Relative expression for gender and the three SNPs analysed using the comparative CT method (∆∆CT).
Variable Control Group (Relative 
expression = 1)
Other group (Relative expression compared to 
the control group, ± SE)
Gender Female Male 0.77 (± 0.07)
val108/158met genotype val/val val/met 1.5 (± 0.11)
met/met 1.3 (± 0.09)
SNP rs_737865 genotype AA AG/GG 0.7 (± 0.07)
SNP rs_165599 genotype AA AG/GG 0.8 (± 0.07)
COMT haplotype (GGG) Haplotype absent Putative haplotype carrier 0.7 (± 0.06)BMC Medical Genetics 2006, 7:10 http://www.biomedcentral.com/1471-2350/7/10
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sion (F = 4.25, 1 df, p = 0.04). We found some evidence to
suggest that COMT is expressed at higher levels in females
than males (F = 5.97, 1 df, p = 0.02). Average CpG meth-
ylation status across all brain samples were 45.4% for site
1 (cytosine 27 in the study of Murphy et al. [28]) and
34.5% for site 2 (cytosine 23). Methylation levels at the
two sites were highly correlated (r = 0.8, p =< 0.000).
Quantitative measurement of the methylation status of
the two promoter CpG sites suggested that there was no
association between methylation level and either disease
status, or expression level. We did, however, find some
preliminary evidence that methylation level was associ-
ated with val158met at site 1 (Regression coefficient 0.26;
t= 2.08; R2 = 0.072; P = 0.042), the relationship was dose-
dependent with val158 homozygotes exhibiting lower lev-
els of methlyation at site 1 than met158 homozygotes. The
same relationship was observed at the second CpG site,
although not significant. (Regression coefficient 0.19; t=
1.4; R2 = 0.021; P = 0.1).
Discussion
In this study we have examined the expression of COMT
in post mortem cerebellum tissue from individuals diag-
nosed with schizophrenia, bipolar disorder, and depres-
sion. Furthermore, we have examined the role of three
polymorphic variants and methylation status at two pro-
moter CpG sites in mediating levels of COMT gene expres-
sion. We found no difference in COMT  expression or
methylation levels in any of the diagnostic groups. How-
ever, we found some evidence to suggest that genotype at
the three SNP polymorphisms is correlated with expres-
sion level in the cerebellum.
We found evidence that the SNPs constituting the Shif-
man et al. "at risk" schizophrenia haplotype [22] are asso-
ciated with changes in COMT  mRNA expression. This
finding is in agreement with those reported by Bray et al.
whose data suggest that the specific COMT  haplotype
implicated in schizophrenia is associated with lower
expression of COMT mRNA [24], a finding also replicated
by Zhu et al. [25]. Our study is the first positive report that
has compared individual genotypes with actual expres-
sion levels, as these previous investigations [24,25] both
examined relative allele-specific expression in hetero-
zygous individuals. It should be noted, however, that
there are two non-replications of the original Bray et al.
finding. Tunbridge et al. examined mRNA derived from
the dorsolateral prefrontal cortex [26]. Using Northern
blotting, they were unable to distinguish any differences
in expression levels between diagnostic groups, or in the
genotypic groups of the val158met SNP. Chen et al. exam-
ined COMT expression levels in post mortem prefrontal
cortex tissue using real-time quantitative PCR, and also
failed to identify any association between any COMT pol-
ymorphism and mRNA expression [11]. They did, how-
ever, find that the val158met polymorphism significantly
affected protein abundance and enzyme activity inde-
pendently of mRNA expression, confirming the thermola-
bility of the met substitution [11].
A number of factors could explain these inconsistent data.
Our study is the only one to examine gene expression in
the cerebellum, and it is possible that tissue-specific gene-
expression differences exist. Furthermore, gene associa-
tion studies of COMT in schizophrenia do not ubiqui-
tously support an aetiological role for variants within the
gene. It is possible that another functional variant else-
where in the gene is mediating the putative val158met
association in some populations via linkage disequilib-
rium (LD). The observation that COMT variants, in partic-
ular the val158met SNP, are in strong LD with variants in
the nearby ARVCF  gene suggest that the alterations in
expression associated with particular COMT  genotypes
seen our data and previous studies by Bray et al. [24] and
Zhu et al. [25] may be mediated by variants not yet fully
investigated. Further work should examine variants in the
VCFS region, in particular the "at risk haplotype" impli-
cated by Sanders et al. that spans the 3'region of COMT
and ARVCF [21], to determine if any of these variants
could be cis  acting factors influencing altered COMT
expression, or to substantiate ARVCF as a candidate gene
in its own right. Overall, given that the met158 allele
encodes an enzyme with reduced thermostability, exhibit-
ing about 60% of the activity of the val158 allele [11], and
that the observed mRNA expression levels associated with
this SNP are not nearly so pronounced, it is likely that this
polymorphism does not have a direct effect on transcrip-
Table 2: ANCOVA analysis of COMT gene expression
Variable F df Significance P value
val158met (rs165688) (val/val versus val/met and met/met combined) 5.7 1 0.020
rs737865 (AA versus AG and GG) 5.134 1 0.028
rs165599 (AA versus AG and GG) 4.18 1 0.046
COMT haplotype (GGG)* *Shifman et al. (2002) "at risk haplotype" 4.25 1 0.044
Gender 5.97 1 0.018
Diagnosis 0.412 3 0.745BMC Medical Genetics 2006, 7:10 http://www.biomedcentral.com/1471-2350/7/10
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tion through for example altering mRNA stability or tran-
scriptional efficiency.
Interestingly, no association has been identified between
COMT expression and disease status in any recent study so
far. It has been postulated that schizophrenics may show
a decrease in COMT  expression [31], paralleling the
22q11 haploinsufficiency seen in individuals with VCFS,
who are at greater risk of developing schizophrenia. Over-
all, the available data suggest there is a haplotype span-
ning  COMT  associated with a slightly elevated risk to
schizophrenia, which confers a decrease in expression in
COMT mRNA. Because of the absence of any noticeable
decrease in the schizophrenia diagnostic group, it is prob-
able that this decrease in COMT is only present in a sub-
section of the schizophrenia patients, and presents only a
small but detectable increase in risk of developing the dis-
order. However the recent finding of a gene-environment
effect between COMT val158met and cannabis use in schiz-
ophrenia may help to clarify these association findings
[32].
It has been widely postulated that conflicting findings in
genetic studies of schizophrenia and other complex dis-
eases may be a result of epigenetic factors [33]. In this
regard, we decided to investigate the methylation status of
two CpG sites in the S promoter region of the COMT gene,
first identified by Murphy et al [28]. CpG methylation is a
molecular process that is intrinsically linked to the regula-
tion of gene expression. Methylation at CpG sites, princi-
pally located in CpG-islands in the promoter regulatory
regions of many genes, disrupts the binding of transcrip-
tion factors and attracts methyl-binding proteins that are
associated with gene silencing and chromatin compac-
tion. Petronis et al. have argued that these epigenetic
mechanisms can explain a number of the non-Mendelian
features observed in a range of complex psychiatric disor-
ders such as schizophrenia [33]. Unlike DNA sequence
variation, which is generally highly stable, epigenetic
processes are highly dynamic: they can be tissue-specific,
developmentally-regulated, and induced by exposure to a
range of environmental stressors. We found that there was
no difference in the methylation status of these two CpG
sites in any of the diagnostic groups examined. Further-
more, we found no evidence to suggest that methylation
of either of these two sites was strongly correlated with
COMT expression levels. Interestingly, we did observe a
correlation between COMT  genotype and methylation
levels. Whilst this finding is likely to be a spurious artefact,
it is possible that this reflects a difference between the
COMT methylation status of each individuals' two chro-
mosomes, potentially indicative of some form of imprint-
ing.
In this regard it is interesting that in contrast to previous
studies, we found a significant effect of gender on expres-
sion levels, with females exhibiting higher expression of
COMT  than males. Reasons for this inconsistency
between studies could be explained by smaller sample
size and the difference in brain region studied. Tunbridge
et al. [26] along with Bray et al. [24] both investigated
mRNA extracted from prefrontal cortex tissue, raising the
possibility that the gender effect is only evident in the cer-
ebellum. There is substantial evidence supporting sexual
dimorphism in COMT. Most notably, the G-G-G haplo-
type association identified by Shifman et al. was princi-
pally driven by females [22]. Gogos et al. demonstrated a
sexual dimorphism between homozygous COMT  defi-
cient mice, with females exhibiting behavioural deficits in
anxiety tasks in comparison to males [34], while hetero-
zygous COMT deficient males exhibited increased aggres-
sive behaviour. Furthermore, Karayiorgou et al. found a
sexual dimorphic pattern of allele transmission in Obses-
sive-Compulsive Disorder (OCD) and COMT val158met
polymorphism: males showed a significant association
with the met allele, where females showed no association
with either allele [35,36]. COMT is involved in the metab-
olism of catechol-oestrogens [37], which may explain why
we observe that the expression level of COMT is elevated
in females. The sexual dimorphism of COMT expression,
and the possibility of genomic imprinting, is an area that
needs further research before any firm conclusions can be
made.
The main limitation of this work is the lack of specificity
of the COMT probe used to any one form of COMT. MB-
COMT is predominantly the form found in brain [38] but
how these forms differ in different brain regions to what
degree is unknown. Further work should investigate these
findings relevant to the two different COMT species.
Conclusion
To conclude, we have examined the role of COMT expres-
sion in the aetiology of schizophrenia, depression, and
bipolar disorder. We find no evidence to suggest that
COMT expression is altered in any of these forms of psy-
chopathology. Furthermore, we find no difference in
COMT promoter methylation patterns in any diagnostic
category, and find no evidence to suggest that CpG meth-
ylation is directly correlated to gene expression. However,
we do find evidence to suggest sexual dimorphism in the
expression of the COMT  gene, and replicate previous
reports implicating polymorphisms in the COMT gene in
the regulation of mRNA expression.
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